Persistence of Anti-HAV Antibody and Long-Term Protection Conferred by a Single Dose of Live-Attenuated Hepatitis a Vaccine: Results from 17-Year Follow-Up

2018 ◽  
Author(s):  
Ying Chen ◽  
Xin-Jiang Zhang ◽  
Song-Mei Wang ◽  
Jing-Chen Ma ◽  
Zhi-Yong Hao ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatitis A

Long‐term persistence of anti‐HAV antibody conferred by a single dose of live‐attenuated hepatitis A vaccine: results from 17‐year follow‐up

2021 ◽  
Author(s):  
Ying Chen ◽  
Yu‐Liang Zhao ◽  
Zhi‐Yong Hao ◽  
Xin‐Jiang Zhang ◽  
Jing‐Chen Ma ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatitis A

scholarly journals Long term follow-up study to evaluate immunogenicity and safety of a single dose of live attenuated hepatitis a vaccine in children

2015 ◽  
Vol 11 (5) ◽  
pp. 1147-1152 ◽  
Author(s):  
Monjori Mitra ◽  
Nitin Shah ◽  
MMA Faridi ◽  
Apurba Ghosh ◽  
VS Sankaranarayanan ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatitis A ◽  
Follow Up Study ◽  
Long Term Follow Up

scholarly journals Long term Immunogenicity of Single Dose of Live Attenuated Hepatitis A Vaccine in Indian Children — Results of 15-Year Follow-up

2021 ◽  
Vol 58 (8) ◽  
pp. 749-752
Author(s):  
Sheila Bhave ◽  
Amita Sapru ◽  
Ashish Bavdekar ◽  
Rishi Jain ◽  
Khokan Debnath ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatitis A ◽  
Indian Children

Long-Term Persistence of Anti-HAV Antibody Conferred by a Single Dose of Live-Attenuated Hepatitis A Vaccine: Results from 17-Year Follow-Up

2020 ◽  
Author(s):  
Ying Chen ◽  
Song-Mei Wang ◽  
Xin-Jiang Zhang ◽  
Jing-Chen Ma ◽  
Zhi-Yong Hao ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatitis A

Hepatitis A vaccine. A new convenient single-dose schedule with booster when long-term immunization is warranted

Vaccine ◽  
1994 ◽  
Vol 12 (14) ◽  
pp. 1327-1329 ◽  
Author(s):  
Jette Victor ◽  
Jenny Dahl Knudsen ◽  
Lars P. Nielsen ◽  
Anders Fomsgaard ◽  
Søren Thybo ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatitis A ◽  
Dose Schedule

Chronic Non-A, Non-B Hepatitis: A Long-Term Follow-up Study in 49 Patients

1987 ◽  
Vol 22 (9) ◽  
pp. 1115-1122 ◽  
Author(s):  
R. Wejstål ◽  
J. Lindberg ◽  
P. Lundin ◽  
G. Norkrans
Keyword(s):  
Hepatitis A ◽  
Follow Up Study ◽  
Long Term Follow Up

Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients

2009 ◽  
Vol 50 (2) ◽  
pp. 388-393 ◽  
Author(s):  
Mårten Werner ◽  
Sven Almer ◽  
Hanne Prytz ◽  
Stefan Lindgren ◽  
Sven Wallerstedt ◽  
...  
Keyword(s):  
Autoimmune Hepatitis ◽  
Hepatitis A ◽  
Long Term Follow Up

scholarly journals Single dose nonavalent HPV vaccine – need of the hour

2020 ◽  
Vol 10 (2) ◽  
pp. 871-873
Author(s):  
Soma Bandyopadhyay ◽  
Manidip Pal
Keyword(s):  
Single Dose ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Herd Immunity ◽  
Cost Effective ◽  
Quadrivalent Vaccine ◽  
Carcinoma Cervix ◽  
Long Term Follow Up

HPV vaccination of the 9-14 years girl children is the answer to eradicate carcinoma cervix. Nonavalent vaccine provides wider coverage than the quadrivalent vaccine. On long-term follow-up, even after single dose HPV vaccination, antibody titre remains good. Herd immunity also achieved by HPV vaccine. Hence single dose nonavalent HPV vaccination of mass people (sexually naive 9-14 years girl children) can provide almost 100% protections and this will be cost-effective also for developing country.  

scholarly journals Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial

2020 ◽  
Vol 112 (10) ◽  
pp. 1038-1046 ◽  
Author(s):  
Aimée R Kreimer ◽  
Joshua N Sampson ◽  
Carolina Porras ◽  
John T Schiller ◽  
Troy Kemp ◽  
...  
Keyword(s):  
Single Dose ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Vaccine Trial ◽  
Enzyme Linked Immunosorbent Assay ◽  
Virus Like Particle ◽  
Long Term Follow Up ◽  
Antibody Levels

Abstract Background The authors investigated the durability of vaccine efficacy (VE) against human papillomavirus (HPV)16 or 18 infections and antibody response among nonrandomly assigned women who received a single dose of the bivalent HPV vaccine compared with women who received multiple doses and unvaccinated women. Methods HPV infections were compared between HPV16 or 18-vaccinated women aged 18 to 25 years who received one (N = 112), two (N = 62), or three (N = 1365) doses, and age- and geography-matched unvaccinated women (N = 1783) in the long-term follow-up of the Costa Rica HPV Vaccine Trial. Cervical HPV infections were measured at two study visits, approximately 9 and 11 years after initial HPV vaccination, using National Cancer Institute next-generation sequencing TypeSeq1 assay. VE and 95% confidence intervals (CIs) were estimated. HPV16 or 18 antibody levels were measured in all one- and two-dose women, and a subset of three-dose women, using a virus-like particle-based enzyme-linked immunosorbent assay (n = 448). Results Median follow-up for the HPV-vaccinated group was 11.3 years (interquartile range = 10.9–11.7 years) and did not vary by dose group. VE against prevalent HPV16 or 18 infection was 80.2% (95% CI = 70.7% to 87.0%) among three-dose, 83.8% (95% CI = 19.5% to 99.2%) among two-dose, and 82.1% (95% CI = 40.2% to 97.0%) among single-dose women. HPV16 or 18 antibody levels did not qualitatively decline between years four and 11 regardless of the number of doses given, although one-dose titers continue to be statistically significantly lower compared with two- and three-dose titers. Conclusion More than a decade after HPV vaccination, single-dose VE against HPV16 or 18 infection remained high and HPV16 or 18 antibodies remained stable. A single dose of bivalent HPV vaccine may induce sufficiently durable protection that obviates the need for more doses.

Sign in / Sign up

Export Citation Format

Share Document